Evaluation of insulin sensitivity in hyperprolactinemic subjects by euglycemic hyperinsulinemic clamp technique

Pituitary

Volumn 12, Issue 4, 2009, Pages 330-334

  Tuzcu, Alpaslan ^a   Yalaki, Serkan ^a   Arikan, Senay ^a   Gokalp, Deniz ^a   Bahcec, Mithat ^a   Tuzcu, Sadiye ^a  

^a DICLE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

Euglycemic clamp; HOMA B; HOMA IR; Hyperprolactinemia; Insulin resistance

Indexed keywords

C PEPTIDE; CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROLACTIN;

ADULT; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; EUGLYCEMIC HYPERINSULINEMIC CLAMP TECHNIQUE; FAT CONTENT; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE CLAMP TECHNIQUE; GOLD STANDARD; HUMAN; HYPERPROLACTINEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; MALE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

ADULT; BLOOD GLUCOSE; FEMALE; GLUCOSE CLAMP TECHNIQUE; HUMANS; HYPERPROLACTINEMIA; IMMUNOASSAY; INSULIN RESISTANCE; LIPIDS; MALE; PROLACTIN; REFERENCE VALUES; YOUNG ADULT;

EID: 70350294653     PISSN: 1386341X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11102-009-0183-1     Document Type: Article

References (29)

1. Baptista T et al (2004) Comparative effects of the antipsychotics sulpiride and risperidone in female rats on energy balance, body composition, fat morphology and macronutrient selection. Prog Neuropsychopharmacol Biol Psychiatry 28:1305-1311. doi: 10.1016/ j.pnpbp.2004.08.001
2. Knudtzon J, Johansen PW, Haug E, Gautvik K (1986) Effects of hypersecretion of growth hormone and prolactin on plasma levels of glucagon and insulin in GH3-celltumor-bearing rats, and the influence of bromocriptine treatment. Life Sci 39:617-621. doi: 10.1016/ 0024-3205(86)90042-1
3. Byatt JC, Staten NR, Salsgiver WJ, Kostelc JG, Collier RJ (1993) Stimulation of food intake and weight gain in mature female rats by bovine prolactin and bovine growth hormone. Am J Physiol 264:E986-E992
4. Moore BJ, Gerardo-Gettens T, Horwitz BA, Stern JS (1986) Hyperprolactinemia stimulates food intake in the female rat. Brain Res Bull 17:563-569. doi: 10.1016/0361-9230(86)90226-1
5. Baptista T, Lacruz A, de Mendoza S, Mendoza Guillén JM, Silvera R, Angeles F, Mendoza MT, Hernández L (2000) Body weight gain after administration of antipsychotic drugs: Correlation with leptin, insulin and reproductive hormones. Pharmacopsychiatry 33:81-88. doi: 10.1055/s-2000-8451
6. Doknic M, Pekic S, Zarkovic M, Medic-Stojanoska M, Dieguez C, Casanueva F, Popovic V (2002) Dopaminergic tone and obesity: An insight from prolactinomas treated with bromocriptine. Eur J Endocrinol 147:77-84. doi: 10.1530/eje.0.1470077
7. Greenman Y, Tordjman K, Stern N (1998) Increased body weight associated with prolactin secreting pituitary adenomas: Weight loss with normalization of prolactin levels. Clin Endocrinol (Oxf) 48:547-553. doi: 10.1046/j.1365-2265.1998.00403.x
8. Brandebourg T, Hugo E, Ben-Jonathan N (2007) Adipocyte prolactin: regulation of release and putative functions. Diabetes Obes Metab 9(4):464-476. doi: 10.1111/j.1463-1326.2006.00671.x
9. Serri O, Beauregard H, Rasio E, Hardy J (1986) Decreased sensitivity to insulin in women with microprolactinomas. Fertil Steril 45:572-574
10. Gustafson AB, Banasiak MF, Kalkhoff RK, Hagen TC, Kim HJ (1980) Correlation of hyperprolactinemia with altered plasma insulin and glucagon: Similarity to effects of late human pregnancy. J Clin Endocrinol Metab 51:242-246
11. Schernthaner G, Prager R, Punzengruber C, Luger A (1985) Severe hyperprolactinemia is associated with decreased insulin binding in vitro and insulin resistance in vivo. Diabetologia 28:138-142
12. Bahceci M, Tuzcu A, Bahceci S, Tuzcu S (2003) Is hyperprolactinemia associated with insulin resistance in non-obese patients with polycystic ovary syndrome? J Endocrinol Invest 26(7):655-659
13. Tuzcu A, Bahceci M, Dursun M, Turgut C, Bahceci S (2003) Insulin sensitivity and hyperprolactinemia. J Endocrinol Invest 26(4):341-346
14. Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18(6):499-502
15. De Fronzo RA, Tobin JD, Andres R (1979) Glucose clamp tecnique: A method for quantifying insulin secretation and resistance. Am J Physiol 237:E214-E223
16. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412-419. doi: 10.1007/BF00280883
17. Wallace TM, Levy JC, Matthews DR (2004) Use and abuse of HOMA modeling. Diabetes Care 27:1487-1495. doi: 10.2337/diacare.27.6.1487
18. Pelkonen R, Nikkilä EA, Grahne B (1982) Serum lipids, postheparin plasma lipase activities and glucose tolerance in patients with prolactinoma. Clin Endocrinol (Oxf) 16:383-390
19. Foss MC, Paula FJ, Paccola GM, Piccinato CE (1995) Peripheral glucose metabolism in human hyperprolactinemia. Clin Endocrinol (Oxf) 43:721-726
20. Reis FM, Reis AM, Coimbra CC (1997) Effects of hyperprolactinaemia on glucose tolerance and insulin release in male and female rats. J Endocrinol 153(3):423-428. doi: 10.1677/joe.0.1530423
21. Serri O, Ling L, Mamputu JC, Beauchamp MC, Maingrette F, Renier G (2006) The influences of hyperprolactinemia and obesity on cardiovascular risk markers: Effects of cabergoline therapy. Clin Endocrinol (Oxf) 64:366-370
22. Cincotta AH, Meier AH, Cincotta M Jr (1999) Bromocriptine improves glycaemic control and serum lipid profile in obese Type 2 diabetic subjects: A new approach in the treatment of diabetes. Expert Opin Investig Drugs 8(10):1683-1707
23. Baptista T, Lacruz A, Meza T et al (2001) Antipsychotic drugs and obesity: Is prolactin involved? Can J Psychiatry 46:829-834
24. Creemers LB, Zelissen PM, van't Verlaat JW, Koppeschaar HP (1991) Prolactinoma and body weight: A retrospective study. Acta Endocrinol (Copenh) 125:392-396
25. Kok P, Roelfsema F, Frölich M, Meinders E, Pijl H (2004) Prolactin release is enhanced in proportion to excess visceral fat in obese women. J Clin Endocrinol Metab 89:4445-4449
26. Schmid C, Goede DL, Hauser RS, Brändle M (2006) Increased prevalence of high body mass index in patients presenting with pituitary tumours: Severe obesity in patients with macroprolactinoma. Swiss Med Wkly 138:254-258
27. Asai-Sato M, Okamoto M, Endo M et al (2006) Hypoadiponectinemmia in lean lactating women: Prolactin inhibits adiponectin secretion from human adipocytes. Endocr J 53:555-562
28. Nilsson L, Binart N, Bohlooly YM et al (2005) Prolactin and growth hormone regulate adiponectin secretion and receptor expression in adipose tissue. Biochem Biophys Res Commun 331:1120-1126
29. Fuglsang J, Skjærbæk C, Frystyk J, Flyvbjerg A, Ovesen P (2006) A longitudinal study of serum adiponectin during normal pregnancy. BJOG 113(1):110-113. doi: 10.1111/j.1471-0528.2005.00792.x